Patterns in Spontaneous Adverse Event Reporting Among Branded and Generic Antiepileptic Drugs

被引:16
|
作者
Bohn, J. [1 ,2 ,3 ]
Kortepeter, C. [3 ]
Munoz, M. [3 ]
Simms, K. [3 ]
Montenegro, S. [3 ]
Dal Pan, G. [3 ]
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA
[3] US FDA, Off Surveillance & Epidemiol, Silver Spring, MD USA
关键词
EPILEPSY;
D O I
10.1002/cpt.81
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Spontaneous adverse event reports constitute an important source of information on previously unknown adverse reactions to marketed medicines. However, the dynamics of such reporting following generic introduction are poorly understood. Using adverse event reports on five antiepileptic drugs from the US Food and Drug Administration's Adverse Event Reporting System, we describe temporal trends in adverse event reporting before and after generic introduction, and survey the quality of product-identifying information contained therein. The majority of reports were sent by innovator drug manufacturers while few were sent by generic manufacturers, even when generics accounted for >90% of dispensed prescriptions. We manually reviewed narratives from 2,500 reports and found that the suspect product type (brand or generic) could not be determined in 84% of reports, while generic products (16%) were identified more often than brand-name products (<1%). These results suggest that pharmacovigilance stakeholders should act to promote more detailed reporting practices.
引用
收藏
页码:508 / 517
页数:10
相关论文
共 50 条
  • [1] Patterns in Spontaneous Adverse Event Reporting Among Branded and Generic Antiepileptic Drugs
    Bohn, Justin
    Kortepeter, Cindy
    Munoz, Monica
    Simms, Kelley
    Montenegro, Susan
    Dal Pan, Gerald
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 452 - 452
  • [2] Antiepileptic drugs: generic versus branded treatments
    Heaney, Dominic C.
    Sander, Josemir W.
    [J]. LANCET NEUROLOGY, 2007, 6 (05): : 465 - 468
  • [3] Lower Proportion of Spontaneous Adverse Event Reports for Generic Drugs by Comparison With Original Branded Drugs at the Postmarket Stage in Japan
    Takami, Akina
    Hirata, Kaori
    Ishiguro, Chieko
    Hanaoka, Hideki
    Uyama, Yoshiaki
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (06) : 1471 - 1476
  • [4] Identification of Generic Drugs in the FDA Adverse Event Reporting System
    Iyer, Geetha S.
    Marimuthu, Sathiya Priya
    Segal, Jodi B.
    Singh, Sonal
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 406 - 407
  • [5] An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System
    Geetha Iyer
    Sathiya Priya Marimuthu
    Jodi B. Segal
    Sonal Singh
    [J]. Drug Safety, 2017, 40 : 799 - 808
  • [6] An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System
    Iyer, Geetha
    Marimuthu, Sathiya Priya
    Segal, Jodi B.
    Singh, Sonal
    [J]. DRUG SAFETY, 2017, 40 (09) : 799 - 808
  • [7] Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the US Food and Drug Administration Adverse Event Reporting System (FAERS)
    Rahman, Md. Motiur
    Alatawi, Yasser
    Cheng, Ning
    Qian, Jingjing
    Plotkina, Annya V.
    Peissig, Peggy L.
    Berg, Richard L.
    Page, David
    Hansen, Richard A.
    [J]. EPILEPSY RESEARCH, 2017, 135 : 71 - 78
  • [8] Adverse Event Reporting Patterns of Newly Approved Drugs in the USA in 2006: An Analysis of FDA Adverse Event Reporting System Data
    Pankdeep Chhabra
    Xing Chen
    Sheila R. Weiss
    [J]. Drug Safety, 2013, 36 : 1117 - 1123
  • [9] Adverse Event Reporting Patterns of Newly Approved Drugs in the USA in 2006: An Analysis of FDA Adverse Event Reporting System Data
    Chhabra, Pankdeep
    Chen, Xing
    Weiss, Sheila R.
    [J]. DRUG SAFETY, 2013, 36 (11) : 1117 - 1123
  • [10] Adverse Event Reporting for Compounded Drugs
    不详
    [J]. BIOPHARM INTERNATIONAL, 2019, 32 (10) : 10 - 10